Drug data last refreshed 3m ago · AI intelligence enriched 5d ago
OPHTHOCORT is a fixed-combination ophthalmic ointment containing chloramphenicol (antibiotic), hydrocortisone acetate (corticosteroid), and polymyxin B sulfate (antibiotic) approved in 1958. It is indicated for bacterial eye infections with inflammatory components. The combination provides broad-spectrum antimicrobial coverage while reducing ocular inflammation.
As LOE approaches, the brand team is likely consolidating focus on legacy market maintenance rather than expansion; headcount may shift toward lifecycle extension or wind-down planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on OPHTHOCORT offers stability in a mature, well-understood therapeutic area but limited growth trajectory; the approaching LOE signals career risk unless you transition to adjacent Pfizer ophthalmology assets or broader company roles. This role is best suited for professionals seeking operational expertise in legacy product management or those transitioning toward portfolio rationalization and business wind-down.
Worked on OPHTHOCORT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.